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Abstract Merkel cell carcinoma (MCC) is a rare cutane-
ous neuroendocrine neoplasm of possible viral origin and is
known for its aggressive behavior. The incidence of MCC
has increased in the last 15 years. Merkel cell carcinoma has
the potential to metastasize, but rarely involves the central
nervous system. Herein, we report three consecutive surgical
cases of MCC presenting at a single institution within 1 year.
We used intracavitary BCNU wafers (Gliadel) in two
cases. Pathological features, including CK20 positivity,
consistent with MCC, were present in all cases. We found 33
published cases of MCC with CNS involvement. We suggest
that the incidence of neurometastatic MCC may be
increasing, parallel to the increasing incidence of primary
MCC. We propose a role for intracavitary BCNU wafers in
the treatment of intra-axial neurometastatic MCC.
Keywords Merkel cell carcinoma  Gliadel  BCNU 
Metastasis  Brain
Introduction
Merkel cell carcinoma (MCC) is a rare cutaneous neuro-
endocrine neoplasm. The prognosis for MCC is poor and
the 5-year disease-specific survival is 64% [1]. Patients
present with painless erythematous to violaceous nodules
on sun exposed regions of the skin. The tumors may
ulcerate and grow rapidly within the first few months.
Heath et al. highlighted the typical clinical features of this
rare form of skin cancer with the acronym ‘‘AEIOU’’
(Asymptomatic, Enlarging rapidly, Immunosuppression,
Older age [50, UV exposed site) [2]. Merkel cell carci-
noma is locally aggressive with a high rate of local
recurrence, regional lymph node involvement, and metas-
tasis. Up to 21% of cases develop distant metastatic disease
[1]. Common sites of distant metastatic involvement are
the skin, lymph nodes, mediastinum, liver, lung, and bone
[3, 4]. Feng et al. [3] reported in 2008 the discovery of a
novel polyomavirus—designated Merkel cell polyomavirus
(MCPyV)—which was integrated into the genome of 8 out
of 10 MCC tumor specimens. Sihto et al. [4] mirrored this
finding in a Finnish population-based pathologic analysis,
detecting MCPyV DNA in 79.8% of 144 formalin-fixed
paraffin embedded MCC specimens that were available for
analysis by polymerase chain reaction.
Central nervous system involvement is rare but can
occur through hematogenous, lymphatic, or direct exten-
sion pathways, and can also undergo dissemination
through the cerebrospinal fluid. We identified thirty-three
prior cases of neurometastatic MCC in the literature,
including both intra-axial and extra-axial transcalvarial
disease [3, 5–35]. We herein describe three additional
surgical cases of neurometastatic MCC that presented
within 1 year at a single institution. We employed the
novel treatment strategy of implanting intracavitary BCNU
wafers (Gliadel) in two of the intra-axial cases at the time
of resection. Neurometastatic MCC may be emerging as a
more common entity than previously thought. The suc-
cession of cases we encountered in a short time may
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suggest an increasing need to address neurometastatic
MCC in light of the increased overall incidence of MCC.
Methods
The senior author treated three surgical cases of MCC
within 1 year. The medical records were reviewed. Case
reports, case series, and literature reviews were identified
with a PubMed search using the keywords ‘‘MCC’’ and
‘‘brain’’ without any search limitations. From the refer-
ences in articles identified through PubMed and found to be
relevant, a search was performed using the Web of Science
to locate additional case reports, case series or literature
reviews cited by the original group of reports derived from
PubMed.
Cases
Case 1
A 75-year-old female presented in December 2008 with
3 weeks of acute onset confusion, ataxia, and left sided
weakness. She had a series of falling episodes 3 weeks
prior to presentation. Computed tomography showed a
2.5 cm hyperdense right parietal mass associated with
edema. Her past medical history was significant for a
20 pound weight loss over the past year, chronic urinary
tract infections, recurrent basal cell carcinoma, and MCC
of the left nasal ala which had been removed 1 year earlier
using Mohs micrographic resection followed by adjuvant
radiation. Imaging showed a 4 cm cystic-solid intra-axial
mass in the right parietal region (Fig. 1a, b). She underwent
right parietal craniotomy and gross total resection with
implantation of intracavitary BCNU wafers (Gliadel)
followed by adjuvant radiotherapy. She died of systemic
complications 7 months after being diagnosed with neu-
rometastatic MCC, and 2 years after her initial diagnosis of
cutaneous MCC.
Case 2
A 51-year-old female presented in January 2008 with
intermittent headaches and nausea for 2 months. She had a
Mohs procedure for MCC of the right calf 4 years earlier.
Metastatic progression was treated with resection of right
inguinal lymph nodes in 2004, and splenectomy and right
salpingo-oophorectomy in 2006. The MRI demonstrated a
3.2 9 3.2 9 2.6 cm right posterior temporal lobe enhanc-
ing mass with considerable surrounding edema, mass
effect, and right-to-left midline shift (Fig. 1c, d). She
underwent craniotomy and gross total resection with
implantation of BCNU (Gliadel) intracavitary wafers, as
well as adjuvant whole brain radiation. In August of 2008,
a radical left neck dissection was undertaken for MCC
involvement of the left trapezius muscle and cervical,
supraclavicular, and sub trapezius lymph nodes. At
21 months after craniotomy, the patient had occasional
memory and balance trouble but was working full time.
She had no evidence of radiographic recurrence on follow-
up MRI.
Case 3
A 77-year-old female presented with headaches and
swelling and tenderness of the left frontoparietal scalp in
July of 2008. Seven months prior to presentation, she
noticed a slight bump on her head that gradually enlarged
and became painful. The past medical history was signifi-
cant only for cataracts and left retinal detachment. The
review of systems was positive for a 10 pound weight loss
and easy bruising. On physical exam, a 6.0 9 7.0 cm mass
over the left anterior parietal area was noted. Magnetic
resonance imaging revealed a heterogeneously enhancing
necrotic left parietal scalp mass extending into the
Fig. 1 T1-weighted gadolinium-enhanced pre-operative MRI of the
brain from Case 1 in axial a and coronal b sections demonstrating an
irregularly enhancing and partially cystic lesion in the right parietal
lobe, with minimal surrounding edema. T1-weighted gadolinium-
enhanced pre-operative MRI of the brain from Case 2 in axial c and
coronal d sections demonstrating an irregularly enhancing lesion in
the right posterior temporal lobe, with minimal surrounding edema
and shift of the midline structures to the left
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subgaleal and epidural spaces and infiltrating the bone
(Fig. 2a, b). A CT scan of the head similarly showed
extensive subgaleal tumor subtended by epidural tumor
(Fig. 2c). There was some subtle calvarial change with
remodeling, but no evidence of gross osteolysis. A trans-
cutaneous biopsy in the clinic revealed a poorly differen-
tiated carcinoma but prolonged formalin fixation precluded
further diagnosis. She underwent a left parietal craniec-
tomy and resection of the lesion. Intraoperatively, the
tumor was entirely subgaleal, with involvement of the
periosteum. No dermal involvement was noted. The bone
was mottled with some evidence of remodeling. The mass
was peeled off the dura. The resected calvarium was ele-
vated as a free flap and was structurally intact. We were
therefore able to utilize the resected bone as a template to
fashion an anatomically precise titanium mesh and meth-
ylmethacrylate cranioplasty before sending the specimen to
pathology (Fig. 2d). Pathologic analysis revealed MCC.
The patient refused adjuvant radiation or chemotherapy.
She was without apparent recurrence until 16 months after
surgery, at which time local and contralateral CNS recur-
rence of the tumor involving scalp, skull, and dura occur-
red, both ipsilaterally at the margin of the prior resection,
and contralaterally in a non-contiguous location involving
again the calvaria, dura, and subgaleal space. The patient
declined any further therapy.
Pathology
All three CNS specimens had similar gross and micro-
scopic features. The gross specimens were pink-tan. Foci of
necrosis were noted in Case 1 and 2 and abundant areas of
both hemorrhage and necrosis were noted in case 2. His-
tological study revealed dyshesive cells arranged in an ill-
defined nodular and focally trabecular pattern (Fig. 3a).
This highly cellular uniform population of small round
cells had scant eosinophilic rims of cytoplasm and round
vesicular nuclei with inconspicuous nucleoli. There were
numerous mitotic figures. Immunohistochemistry with
cytokeratin 20 (CK20) displayed paranuclear staining
pattern in all three cases (Fig. 3b). Electron microscopy
was performed on Case 2 and demonstrated a neo-
plasm with clumped nuclear chromatin and scant cyto-
plasm filled with dispersed ribosomes and mitochondria.
Fig. 2 T1-weighted gadolinium-enhanced pre-operative MRI of the
brain from Case 3 in axial a and coronal b sections demonstrating a
subgaleal mass with involvement of the underlying bone and dura.
Pre-operative axial head CT with bone windows c scan demonstrates
subtle bony change with slightly irregular hyperostotic calvarium, but
no gross osteolysis. Postoperative axial head CT shows the region of
calvarial reconstruction with titanium mesh and methylmethacrylate d
Fig. 3 Case 2 a Light micrograph of the metastatic MCC specimen
stained with hematoxylin and eosin at 960 magnification shows a
highly cellular specimen comprised of small to medium sized round
cells with high nuclear to cytoplasmic ratio. The oval nuclei have a
fine granular chromatin pattern. Mitotic figures were evident. b Light
micrograph of the metastatic MCC specimen stained with CK-20 at
960 magnification displays the paranuclear dot staining pattern
typical of MCC
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Higher magnification showed scattered nuclei with dense
granular nuclear inclusions. In Case 2, cytogenetics was
done and yielded a translocation, t (7; 11). Pathologic
samples were analyzed for the presence of polyomavirus.
On agarose gel electrophoresis, bands were identified that
were consistent with expected size of polyomavirus PCR
product from all samples, but after the sequencing and
analysis using the Genbank database, the sequences did not
match polyomavirus. Based on these findings, polyomavi-
rus in these samples could not be detected.
Literature review
We identified 33 cases of neurometastatic MCC from a
review of the literature (Table 1) [5–20, 29, 30]. Five of
these cases were reported in the context of case series for
which individual patient data was not available [18, 21,
29]. Several duplicate cases were identified which had been
previously published [22, 23]. The mean age of patients
was 63 ± 11 years. Neurometastatic disease in MCC
appeared at the time of initial diagnosis in eight cases,
typically in association with disease associated with a scalp
or head and neck lesion extending directly through the
calvaria or skull base into the intracranial space. Alterna-
tively, neurometastatic disease was delayed over 3 years
from the time of initial MCC diagnosis in 18% of cases for
which data was available. For those patients who presented
with intraparenchymal brain lesions without transcalvarial
involvement, the median time delay after the diagnosis of
the primary cutaneous lesion was 16 months. The mean
survival time after a diagnosis of CNS metastasis including
transcalvarial metastasis was estimated as greater than or
equal to 10 months and the median survival time was
greater than or equal to 8.5 months.
We attempted to stratify the cases based on treatment
received prior to the development of neurometastatic dis-
ease. The data was too limited and varied to draw any
meaningful conclusions. Progression and survival times
were variously reported in years or months, and often the
time had to be inferred. In 8 out of 36 cases, there was
insufficient data regarding treatment or follow-up. In eight
more cases, the CNS disease was discovered at the time of
initial presentation of MCC. All cases with prior disease
were treated with surgical resection of the primary lesion,
and various combinations of chemotherapy and radiation
therapy were applied to a subset of cases (Table 1). There
was no difference from the time of initial diagnosis to
neurometastatic progression between resection of the pri-
mary lesion alone versus various combinations of adjuvant
therapy (21 M ± 16 M and 22 M ± 16 M, P = 0.9).
When we examined the available data on the overall sur-
vival, no difference could be detected between those
patients who had resection only and those who had resec-
tion with adjuvant therapy prior to neurometastatic pro-
gression (21 M ± 18 M and 20 M ± 16 M, P = 0.9).
Discussion
First described in 1972 by Tang and Toker [24] MCC is a
rare cutaneous neuroendocrine neoplasm with an aggres-
sive clinical course. The cell of origin is thought to be the
Merkel cell, eponymously named by Robert Bonnet for the
German anatomist Friedrich Sigmund Merkel [25], who
described the cell type in 1875. Merkel cells are primitive
neurons derived from the neural crest, which function as
mechanoceptors for discriminatory light touch but which
also have neuroendocrine function. Merkel cell carcinoma
is a rare form of skin cancer and carries a poor prognosis.
Merkel cell carcinoma has been synonymously referred to
as Merkel cancer, Merkel cell cancer, trabecular carci-
noma, neuroendocrine carcinoma of the skin, primary
small cell carcinoma of the skin, ‘‘murky cell carcinoma’’
and cutaneous apudoma. The mortality rate of MCC is
twice that of melanoma (33 vs. 15%) [26]. Typically,
erythematous to violaceous painless nodules appear on sun-
exposed regions of the skin. Ulceration may occur and the
tumors may grow rapidly within a few months.
The incidence of MCC is rising. Hodgson [27] investi-
gated the incidence trend and found a threefold increase in
incidence within a 15-year period. This may be due to an
increasingly aged population demographic as well as to more
extensive sun exposure. Alternatively, increased awareness
of MCC and more accurate diagnosis through the advent of
the immunohistochemical marker CK20 may account in part
for this increasing trend [2]. This small round cell tumor of
the skin should be distinguished from small cell lung carci-
noma, malignant lymphoma, metastatic primitive neuroen-
docrine tumors, and malignant melanoma [28]. These
entities can be differentiated using histology and immuno-
histochemical markers. Small cell lung cancer and non-small
cell cancer can be ruled out with TTF-1. HMB45 and MelA
are markers for melanoma. CK20 can be used as a marker for
MCC. A paranuclear dot staining pattern of low molecular
weight cytokeratin 20 (CK20) is a hallmark of MCC
(Fig. 3b). Aberrations of chromosome 11 have been seen in
MCC [4, 36, 39] and cytogenetic analysis in Case 2 of the
present series yielded a translocation at this locus.
Merkel cell carcinoma is locally aggressive by direct
tissue extension, spreads to local lymphatic basins, and is
characterized by distant hematogenous metastasis. In one
large series of 251 patients, twenty-one percent developed
distant metastatic disease. The development of distant
metastasis was positively correlated with the stage (I–III)
on presentation, and adjuvant chemotherapy was not
150 J Neurooncol (2011) 102:147–155
123
T
a
b
le
1
R
es
u
lt
s
o
f
li
te
ra
tu
re
re
v
ie
w
P
u
b
li
ca
ti
o
n
A
g
e/
se
x
L
o
ca
ti
o
n
o
f
m
et
as
ta
si
s
T
re
at
m
en
t
p
ri
o
r
to
C
N
S
d
is
ea
se
T
re
at
m
en
t
fo
r
C
N
S
m
et
as
ta
si
s
T
im
e
to
C
N
S
d
is
ea
se
af
te
r
P
ri
m
ar
y
D
x
S
u
rv
iv
al
af
te
r
C
N
S
m
et
as
ta
si
s
O
v
er
al
l
su
rv
iv
al
K
ro
ll
et
al
.
[1
3
]a
4
8
M
B
ra
in
?
?
?
?
?
K
ro
ll
et
al
.
[1
3
]a
7
0
M
B
ra
in
?
?
?
?
?
K
ro
ll
et
al
.
[1
3
]a
7
2
F
M
en
in
g
es
?
?
?
?
?
W
ic
k
et
al
.
[5
]a
6
2
M
B
ra
in
S
R
,
R
T
,
ch
em
o
N
o
tr
ea
tm
en
t
1
2
M
1
M
1
3
M
W
ic
k
et
al
.
[5
]a
7
6
M
B
ra
in
S
R
N
o
tr
ea
tm
en
t
3
Y
0
M
3
6
M
G
o
ep
fe
rt
et
al
.
[1
8
]b
?
B
ra
in
?
?
?
?
?
G
ro
sh
et
al
.
[1
7
]a
5
7
F
B
ra
in
S
R
W
B
R
T
,
ch
em
o
2
M
1
2
M
1
4
M
G
ro
sh
et
al
.
[1
7
]a
5
6
M
B
ra
in
S
R
W
B
R
T
,
ch
em
o
C
2
1
M
?
?
H
it
ch
co
ck
et
al
.
[1
6
]a
5
2
M
B
ra
in
S
R
W
B
R
T
,
ch
em
o
3
M
9
M
1
2
M
K
n
o
x
et
al
.
[1
4
]a
7
5
F
B
ra
in
S
R
,
R
T
,
H
T
W
B
R
T
4
Y
?
?
K
n
o
x
et
al
.
[1
4
]
6
0
M
L
ep
to
m
en
in
g
es
S
R
,
R
T
,
ch
em
o
W
B
R
T
,
IT
ch
em
o
1
0
M
1
4
M
2
4
M
D
u
d
le
y
et
al
.
[3
6
]
6
4
M
L
ep
to
m
en
in
g
es
S
R
,
R
T
,
ch
em
o
N
o
tr
ea
tm
en
t
1
7
M
6
d
ay
s
1
7
M
A
le
x
an
d
er
et
al
.
[3
5
]
5
6
M
B
ra
in
–
B
io
p
sy
,
W
b
rt
,
ch
em
o
P
re
se
n
t
at
d
x
3
Y
3
6
Y
W
o
ja
k
an
d
M
u
ra
li
[3
0
]
7
8
F
C
al
v
ar
ia
,
D
u
ra
–
S
R
,
L
R
T
P
re
se
n
t
at
d
x
C
1
Y
C
1
2
M
M
an
o
m
e
et
al
.
[1
1
]
5
7
F
S
k
u
ll
B
as
e,
B
ra
in
–
R
A
P
re
se
n
t
at
d
x
?
?
S
m
al
l
et
al
.
[8
]
5
6
M
B
ra
in
–
B
io
p
sy
,
W
B
R
T
P
re
se
n
t
at
d
x
2
2
M
2
2
M
Y
ie
n
g
p
ru
k
sa
w
an
et
al
.
[2
9
]a
,b
?
B
ra
in
?
?
?
?
?
S
h
ar
m
a
et
al
.
[9
]a
5
7
M
B
ra
in
–
W
B
R
T
,
C
h
em
o
P
re
se
n
t
at
d
x
1
3
M
1
3
M
S
n
o
d
g
ra
ss
et
al
.
[7
]a
,c
6
1
M
B
ra
in
,
L
ep
to
m
en
in
g
es
S
R
,
ch
em
o
W
B
R
T
,
IT
C
h
em
o
1
Y
6
M
1
8
M
E
ft
ek
h
ar
i
et
al
.
[2
1
]a
,b
?
B
ra
in
?
?
?
?
?
E
ft
ek
h
ar
i
et
al
.
[2
1
]a
,b
?
B
ra
in
?
?
?
?
?
E
ft
ek
h
ar
i
et
al
.
[2
1
]a
,b
?
B
ra
in
?
?
?
?
?
M
at
u
la
et
al
.
[1
0
]
4
7
M
S
k
u
ll
B
as
e,
D
u
ra
,
B
ra
in
–
S
R
,
R
T
,
C
h
em
o
P
re
se
n
t
at
d
x
1
2
M
1
2
M
S
tr
ak
a
et
al
.
[6
]a
7
1
F
B
ra
in
S
R
,
R
T
C
h
em
o
1
0
M
2
M
1
2
M
L
it
o
fs
k
y
et
al
.
[1
2
]
8
6
F
B
ra
in
S
R
S
R
,
R
T
1
6
M
C
8
M
2
4
M
Ik
aw
a
et
al
.
[1
5
]
4
8
F
B
ra
in
S
R
,
R
T
S
R
,
W
B
R
T
?
b
o
o
st
,
ch
em
o
5
Y
1
1
M
7
1
M
E
g
g
er
s
et
al
.
[3
7
]
6
9
M
B
ra
in
,
L
ep
to
m
en
in
g
es
S
R
,
R
T
,
C
h
em
o
W
B
R
T
?
b
o
o
st
1
7
M
\
2
M
1
8
M
B
ar
k
d
u
ll
et
al
.
[3
4
]
5
5
M
C
al
v
ar
ia
,
D
u
ra
–
S
R
,
L
R
T
,
C
h
em
o
P
re
se
n
t
at
d
x
1
0
M
1
0
M
F
ay
e
et
al
.
[2
0
]a
8
5
M
C
al
v
ia
ri
a,
D
u
ra
S
R
,
R
T
C
h
em
o
1
Y
?
?
F
ay
e
et
al
.
[2
0
]
6
8
M
B
ra
in
,
L
ep
to
m
en
in
g
es
S
R
S
R
,
R
T
1
Y
7
M
1
9
M
C
h
an
g
et
al
.
[3
2
]
4
5
M
L
ep
to
m
en
in
g
es
S
R
,
R
T
,
C
h
em
o
IT
C
h
em
o
,
W
B
R
T
2
Y
C
3
M
C
2
5
M
D
e
C
ic
co
et
al
.
[3
8
]a
6
9
M
B
ra
in
S
R
,
C
h
em
o
N
o
tr
ea
tm
en
t
2
2
M
6
M
2
8
M
F
el
et
ti
et
al
.
[1
9
]
6
5
F
P
it
u
it
ar
y
S
R
S
R
,
R
ad
io
su
rg
er
y
,
C
h
em
o
3
.5
Y
C
8
M
C
5
0
M
P
re
se
n
t
se
ri
es
7
5
F
B
ra
in
S
R
S
R
?
IC
C
,
W
B
R
T
1
Y
7
M
1
9
M
J Neurooncol (2011) 102:147–155 151
123
protective against spread [1]. The most common locations
for metastasis include the liver, mediastinum, and para-
aortic lymph nodes [1]. Voog et al. [31] reviewed 107
cases of MCC complied from the literature, and found the
following metastatic sites: skin (33%), lymph nodes (32%),
liver (16%), lung (12%), bone (11%), brain (7%), and less
than 2% each for bone marrow, pleura, pancreas, testis,
small bowel, and stomach.
Central nervous system involvement of MCC is thought of
as a rare event [7, 19, 32], although an early case series of 30
patients with ‘‘trabecular carcinoma’’ (aka MCC) revealed
that 10% had CNS involvement (two cases involving brain
and one involving the meninges) [13]. Eftekhari found only
three cases of brain involvement among a series of 93 patients
with MCC (3%) [21] and Yiengspruksawan [29] mentioned
one instance of brain involvement within a series of 70
patients (*1%). Since 1982, a steady trickle of case reports
describing neurometastatic MCC have been published
(Fig. 4). We note however that it is impossible draw any
conclusions about incidence rate from reviewing the publi-
cation of case reports. An increased length of survival after
diagnosis, made possible through multimodal therapies for
primary disease, may lead to an increased incidence of neu-
rometastatic disease. Thirty-three cases have been described
in the literature. We describe three additional cases of neu-
rometastatic disease that presented as a cluster within the
period of 1 year. It is possible that this pattern occurred simply
by chance. Alternatively, these cases may portend a rise in this
neurometastatic histology, driven by the increasing incidence
trends and prolonged survival exposure of MCC overall.
We could not discern any unique demographic or prior
treatment characteristics of the patients in our series. All
were over 50 and in one patient presented with calvarial
and intracranial involvement as a first presentation of
disease. The other two patients had previously had
aggressive local therapy, including Mohs procedures, but
Fig. 4 The graph depicts the cumulative number of case reports and
case series describing neurometastatic MCC vs. the year of
publicationT
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neither had received systemic chemotherapy. We note that
all three of the metastatic MCC specimens in our series
were negative for polyomavirus. This is consistent with the
report by Sihto et al. [4] in which they found that MCPyV-
negative specimens, which comprise 20% of cases of
MCC, were associated with a poorer overall survival and a
greater likelihood for regional nodal metastasis at the time
of initial MCC diagnosis. In an editorial comment,
DeCaprio [33] offers that virally-induced cancer cells may
possess a simpler and less virulent genome, or that viral
interference in host cell signaling mechanisms may render
the transformed cells more susceptible to immune sur-
veillance, unlike the cases in our series.
Merkel cell carcinoma spreads to the CNS primarily
through the blood. Two of the cases in our series and 74% of
the cases from our literature review exhibited hematogenous
metastases to the brain. Further CNS dissemination occurred
through the cerebrospinal fluid in 17% of cases. Access to
the dura and intracranial compartment by MCC occurred
through direct tumor extension through the calvarium or
skull base in six of the total reported cases (17%). In each
instance of transcranial disease, the primary disease occur-
red on the scalp, face, or head and neck. Wojak and Murali
[30] suggest that MCC involving the calvarium may origi-
nate not from normal cutaneous Merkel cells, but from
aberrant rests of cutaneous tissue within the subperiosteal
layer of the skull. Indeed, the patient in Case 3 did not appear
to have evidence of cutaneous disease, and the tumor was
confined to a subgaleal location. Curiously, extensive bony
destruction of the calvarium or skull base does not occur.
The pre-operative CT scan of the head from Case 3 in this
series shows a very limited osteolytic reaction (Fig. 2c) and
at the time of surgery, the resected calvarium was structur-
ally intact. Faye et al. [20] noted no evidence of bone
destruction in a case of transcalvarial MCC. Barkdull et al.
[34] also observed this phenomenon and proposed that the
mechanism of intracranial spread may involve small emis-
sary veins that communicate with the diploic venous chan-
nels of the skull. Intracranial spread of disease in these cases
is not so much direct extension through tissue as it is
hematogenous spread through the local venous drainage
basins, analogous to lymphatic spread of disease. In Case 3
of this series, recurrence occurred in the calvarium and dura,
contralaterally and non-contiguously with the primary
lesion. We speculate that removal of a large portion of the
skull redirected the venous drainage pattern, resulting in
contralateral disease that had the appearance of a lesion
arising from the overlying subperiosteal layer.
The development of distant metastatic disease has been
viewed as a harbinger of death, for which only palliative care
has been offered, and one series reported an 82% death rate
within 5 months of the diagnosis of distant metastasis [18].
In our series, one patient died at 7 months, and the other two
patients are alive, one with recurrence at 16 months (Case 3)
and one with no evidence of disease at 21 months (Case 2).
In the cases reviewed in the Table 1, thirty-eight percent of
cases from the literature review for which follow-up data
were available survived over 1 year, with one patient alive
and well at 3 years [35]. These results suggest an aggressive
approach to local control of CNS disease in MCC.
Treatment for MCC with CNS involvement has involved
resection, chemotherapy, and radiation, but there are no
definitive guidelines. We used intracavitary BCNU wafers
(Gliadel) in cases 1 and 2, which appeared to be effective
in local CNS control, although the patient in case 1 died of
systemic complications of MCC 7 months after the crani-
otomy and tumor resection. Gliadel BCNU (3.85%
1, 3-bis-(2-chloroethyl)-1-nitrosourea) intracavitary che-
motherapy wafers delivers a very high concentration of this
mustard gas-related alkylating agent to the tumor site. It is
typically used in malignant glioma [40], but has also been
demonstrated in a limited pilot study to be effective against
local recurrence in a variety of metastatic brain tumors,
including melanoma [41]. Furthermore, BCNU/Carmustine
has been systemically used in the treatment of MCC [39]. A
precedent therefore exists for its use in conjunction with the
resection of MCC metastases to the brain to prevent recur-
rence. Several of the cases from the literature review had
CNS recurrence [3, 9, 15, 16, 20]. These reports were
reviewed. Time to CNS recurrence was given in four of the
cases and was 8 months, 3 months, 2 years, and 10 months.
The mean recurrence time was 11 ± 9 months. Case 3 from
our series had calvarial and dural recurrence at 16 months
after craniectomy, although Gliadel wafers were not indi-
cated for this case of extra-axial disease. We note that our
treatment strategy using BCNU wafers for intra-axial neu-
rometastatic disease is anecdotal. There is insufficient evi-
dence to suggest a treatment standard for neurometastatic
MCC, but based on the favorable response of this patient and
the treatment rationale, we believe that the use of BCNU
wafers should be considered a viable treatment option.
In summary, neurometastatic MCC may be emerging as a
more common entity than previously thought. CNS
involvement is usually intraparenchymal, but may occur
through direct extension from a lesion and through CSF
dissemination. A literature review revealed 33 neurometa-
static MCC cases over twenty-three years. To this number,
we add three cases that presented within 1 year at a single
institution. Intracavitary BCNU may help prevent local
recurrence. The succession of cases we encountered in a
short time and the relatively favorable outcomes in one of the
cases calls attention to neurometastatic MCC and suggests
an aggressive approach to local control of CNS disease.
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